Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Nuvaxovid JN.1 dispersion for injection in pre-filled syringe {equilateral_black_triangle}

Active Ingredient:
SARS-CoV-2 recombinant spike protein
Company:  
SANOFI See contact details
ATC code: 
J07BN04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Product Information
{arrow_left}
{arrow_right}
{healthcare_pro_orange} For Healthcare Professionals

A Change of Ownership application has been approved by the MHRA to transfer the licence for Nuvaxovid (COVID-19 Vaccine (recombinant, adjuvanted)) from Novavax CZ a.s. to Aventis Pharma Limited (trading as Sanofi). The approved Sanofi SmPC and PIL for Nuvaxovid JN.1 dispersion for injection in pre-filled syringe are provided here for ease of reference.

SANOFI
Company image
Address
Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0)800 035 2525
Telephone
+44 (0)118 354 3000